Tirzepatide (Zepbound) Approved for Chronic Weight Management

from Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives · host Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

In this episode, hosts discuss the FDA's approval of tirzeptiade (Zepbound) as an adjunct to lifestyle modification for the chronic weight management in people with overweight or obesity.

Episode metadata supplied by the publisher feed · Published Nov 8, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

Tirzepatide (Zepbound) Approved for Chronic Weight Management

0:00 14:34

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives?

This episode is 14 minutes long.

When was this Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives episode published?

This episode was published on November 8, 2023.

Can I download this Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!